Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/Sitagliptin - GL PharmTech

Next Previous
X
Search
Drug Profile

Dapagliflozin/Sitagliptin - GL PharmTech

Alternative Names: GLK-2DS

Latest Information Update: 21 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GL PharmTech
  • Class Anti-ischaemics; Antihyperglycaemics; Antineoplastics; Antivirals; Azoles; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Fluorobenzenes; Gene therapies; Glucosides; Heart failure therapies; Hepatoprotectants; Immunotherapies; Ketones; Obesity therapies; Pyrans; Pyrazines; Small molecules; T lymphocyte cell therapies; Triazoles; Urologics
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Diabetes mellitus

Most Recent Events

  • 05 Sep 2024 Preregistration for Diabetes mellitus in South Korea (PO) (GL PharmTech pipeline, September 2024)
  • 04 Sep 2024 Phase-I clinical trials in Diabetes mellitus (PO), before September 2024 (GL Pharmtech pipeline, September 2024)
  • 22 Mar 2021 Ministry of Food and Drug Safety approves IND application for dapagliflozin/sitagliptin in Diabetes mellitus

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top